Published in Hepatitis Weekly, October 27th, 2003
"Creatine monohydrate (CrM) supplementation appears to be relatively safe based on data from short-term and intermediate-term human studies and results from several therapeutic trials. The purpose of the current study was to characterize pathological changes after intermediate-term and long-term CrM supplementation in mice [healthy control and SOD1 (G93A) transgenic] and rats (prednisolone and nonprednisolone treated)," according to researchers in Canada.
"Histological assessment (18-20 organs/tissues) was performed on G93A mice after 159 days and in Sprague-Dawley rats after 365 days...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly